Novo Nordisk A/s

Peter Kurtzhals

Svend Havelund

Ib Jonassen

Per Hertz Hansen

Jan Markussen

Niels Christian Kaarsholm

Jakob Brandt

John Halstro Slashedm

John B Halstrøm

A pharmacologically active peptide hormone derivative in which the parent peptide hormone has been modified by introducing either a lipophilic substituent, W, in the N-terminal amino acid or a lipophilic substituent, Z, in the C-terminal amino acid of the parent peptide hormone or an analogue thereof, said lipophilic substituent having from 8 to 40 carbon atoms, has a protracted profile of action.

Peptide derivatives

The present invention relates to insulin derivatives in which a lipophilic group having from 12 to 40 carbon atoms is attached to the &#x3b1;-amino group of the N-terminal amino acid in the B-chain or to the carboxy group of the C-terminal amino acid in the B-chain have a protracted profile of action.

Insulin derivatives

The present invention relates to insulin derivatives in which a lipophilic group having from 12 to 40 carbon atoms is attached to the &agr;-amino group of the N-terminal amino acid in the B-chain or to the carboxy group of the C-terminal amino acid in the B-chain have a protracted profile of action.

The present invention relates to a pharmacologically active peptide hormone derivative in which the parent peptide hormone has been modified by introducing either a lipophilic substituent, W, in the N-terminal amino acid or a lipophilic substituent, Z, in the C-terminal amino acid of the parent peptide hormone or an analogue thereof, said lipophilic substituent having from 8 to 40 carbon atoms, has a protracted profile of action.

Growing community of inventors

Taastrup, Denmark

Peter Kurtzhals